5 Best Global Stocks to Buy According to Wall Street Analysts

3. BioNTech SE (NASDAQ:BNTX)

Upside Potential as of April 20: 27.29% 

BioNTech SE (NASDAQ:BNTX) is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases.

On April 13, BofA raised its price target on BioNTech SE (NASDAQ:BNTX) from $128 to $130, while maintaining a ‘Buy’ rating on the shares. The revised target indicates an upside of almost 20% from the current price levels.

The move comes after BioNTech SE (NASDAQ:BNTX) reported positive Phase 2 results for T-Pam in second-line and later HER2-expressing endometrial cancer. The analyst firm found these results encouraging and noted that they support a potential first approval within BioNTech’s expanding oncology pipeline.

BioNTech SE (NASDAQ:BNTX) is targeting total revenues in the range of €2 billion to €2.3 billion for FY 2026, down from €2.9 billion in 2025. The company expects lower revenue from the COVID-19 vaccine it developed in partnership with Pfizer, driven by declines in both the European and United States markets. Moreover, the YoY decline comes from a lack of expected one-time revenues, such as payments from Pfizer’s opt-out of the shingles program last year.